Search results
Results from the WOW.Com Content Network
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [15] Lisdexamfetamine is taken by mouth. Its effects generally begin within two hours ...
Country Drug and precursor laws Germany: Anlage I [8] Anlage II [9] Anlage III [10] Sweden: Narkotikastrafflagen. Läkemedelsverkets föreskrifter om förteckningar över narkotika [11] Lagen om förbud mot vissa hälsofarliga varor. List of substances [12] Kontroll av narkotikaprekursorer [permanent dead link ] (up to date list of laws) New ...
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain
The Drug Enforcement Administration is increasing the production limit of Vyvanse and its generic equivalents by about 24% to address the ongoing global shortage of ADHD medications.
The illegal drug trade in Japan is the illegal production, transport, sale, and use of prohibited drugs in Japan.The drug trade is influenced by various factors, including history, economic conditions, and cultural norms.
This is a list of investigational attention deficit hyperactivity disorder drugs, or drugs that are currently under development for clinical use in the treatment of attention deficit hyperactivity disorder (ADHD) but are not yet approved.
1. Ritz Crackers. Wouldn't ya know, a cracker that's all the rage in America is considered an outrage abroad. Ritz crackers are outlawed in several other countries, including the United Kingdom ...
Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019. Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions.